Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

CUETO Risk Score (BCG-Treated)

The CUETO (Club Urológico Español de Tratamiento Oncológico) model is specifically validated for NMIBC patients treated with BCG immunotherapy.

Evidence-based context for fast calculator use

Purpose:
CUETO score predicts 5-year recurrence and progression risk in non-muscle invasive bladder cancer patients treated with BCG immunotherapy.
Population:
patients with non-muscle-invasive or urothelial cancer in the recurrence/progression setting described by the model
Factors:
Gender, Age, Recurrence Status, Number of Tumors, T Category, Carcinoma In Situ, Grade
Reference:
Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195-2203.
HomeCUETO Risk Score (BCG-Treated)
Pin your most used calculators here by clicking the star in the dropdown.

CUETO Risk Score (BCG-Treated)

Clinical Context & Background

The CUETO (Club Urológico Español de Tratamiento Oncológico) model is specifically validated for NMIBC patients treated with BCG immunotherapy. It often provides more accurate (and lower) risk estimates for this population compared to the EORTC tables, which were derived largely from chemotherapy-treated patients.
Primary Source EvidenceFernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195-2203.
Formula Logic
Sum of points for Gender, Age, Recurrence Status, Tumors, T-stage, CIS, and Grade.

Reference Data

Score5-Year Recurrence Risk5-Year Progression Risk
0 - 419.1%Prog Score 0-6: < 9%
5 - 635.6%Prog Score 0-6: < 9%
7 - 847.5%Prog Score >6: ~ 15-30%
> 860.5%Prog Score >6: ~ 15-30%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use CUETO Risk Score (BCG-Treated) when cUETO score predicts 5-year recurrence and progression risk in non-muscle invasive bladder cancer patients treated with BCG immunotherapy.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 4 through > 8.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm stage, grade, CIS, tumor number and size, prior recurrence, BCG exposure, pathology review, and guideline risk group.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Historical EORTC, CUETO, and contemporary EAU groups use different populations and should not be interchanged.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with non-muscle-invasive or urothelial cancer in the recurrence/progression setting described by the model

How to apply this result

For a representative case, verify Gender, Age, Recurrence Status, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

EORTC NMIBC Risk Calculator — Bladder Cancer Recurrence & ProgressionEAU NMIBC Risk Stratification (2024)

Frequently Asked Questions

When should CUETO Risk Score (BCG-Treated) be used?

Use it for patients with non-muscle-invasive or urothelial cancer in the recurrence/progression setting described by the model when all required inputs and the intended clinical setting are confirmed.

Can CUETO Risk Score (BCG-Treated) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.